How can nanotechnology help to combat COVID-19? Opportunities and urgent need

Abstract

Incidents of viral outbreaks have increased at an alarming rate over the past decades. The most recent human coronavirus known as COVID-19 (SARS-CoV-2) has already spread around the world and shown R 0 values from 2.2 to 2.68. However, the ratio between mortality and number of infections seems to be lower in this case in comparison to other human coronaviruses (such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)). These outbreaks have tested the limits of healthcare systems and have posed serious questions about management using conventional therapies and diagnostic tools. In this regard, the use of nanotechnology offers new opportunities for the development of novel strategies in terms of prevention, diagnosis and treatment of COVID-19 and other viral infections. In this review, we discuss the use of nanotechnology for COVID-19 virus management by the development of nano-based materials, such as disinfectants, personal protective equipment, diagnostic systems and nanocarrier systems, for treatments and vaccine development, as well as the challenges and drawbacks that need addressing.

References 208

1. 1.

   Dhama K, Pawaiya RVS, Chakrabort S, Tiwari R, Saminathan M, Verma AK. Coronavirus infection in equines: a review. Asian J Anim Vet Adv. 2014;9:164-176.

   Not in our library

2. 2.
   Coronavirus envelope protein: current knowledge · 2019

   No notice
3. 3.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
4. 4.

   Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-1207.

   Not in our library10.1056/nejmoa2001316

5. 5.

   Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.

   Not in our library10.1016/s0140-6736(20)30211-7

6. 6.

   Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27:taaa021.

   Not in our library10.1093/jtm/taaa021

7. 7.

   Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica Atenei Parmensis. 2020;91:157-160.

   Not in our library10.23750/abm.v91i1.9397

8. 8.

   Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-192.

   Not in our library10.1038/s41579-018-0118-9

9. 9.

   Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

   Not in our library10.1016/s0140-6736(20)30251-8

10. 10.
    A new coronavirus associated with human respiratory disease in China · 2020

    Corrected
11. 11.

    Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127-20.

    Not in our library10.1128/jvi.00127-20

12. 12.

    Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Mol Biol. 2020.

    Not in our library10.1101/2020.01.31.929042

13. 13.

    Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260-1263.

    Not in our library10.1126/science.abb2507

14. 14.

    Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562-569.

    Not in our library10.1038/s41564-020-0688-y

15. 15.
    A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) · 2020

    No notice
16. 16.

    Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395:e35-e36.

    Not in our library10.1016/s0140-6736(20)30305-6

17. 17.
    Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan · 2020

    Corrected
18. 18.

    Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. COVID-19: a promising cure for the global panic. Sci Total Environ. 2020;725:138277.

    Not in our library10.1016/j.scitotenv.2020.138277

19. 19.

    Hui L, Yeming W, Jiuyang X, Bin C. Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin J Tuberc Respir Dis. 2020;43:170-172.

    Not in our library10.3760/cma.j.issn.1001-0939.2020.03.004

20. 20.

    Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8:e11-e12.

    Not in our library10.1016/s2213-2600(20)30071-0

21. 21.

    Xia B, Kang X. Activation and maturation of SARS-CoV main protease. Protein Cell. 2011;2:282-290.

    Not in our library10.1007/s13238-011-1034-1

22. 22.

    Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55:105950.

    Not in our library10.1016/j.ijantimicag.2020.105950

23. 23.

    Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin N Am. 2010;24:413-437.

    Not in our library10.1016/j.idc.2010.01.001

24. 24.

    Jackman JA, Lee J, Cho N-J. Nanomedicine for infectious disease applications: innovation towards broad-spectrum treatment of viral infections. Small. 2016;12:1133-1139.

    Not in our library10.1002/smll.201500854

25. 25.

    Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;7:61-64.

    Not in our library10.1007/s40475-020-00201-6

26. 26.

    Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, Alonso R, Herranz-Alonso A, Sanjurjo-Sáez M. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 2018;52:11-18.

    Not in our library10.1177/1060028017728294

27. 27.

    Mohammadi Pour P, Fakhri S, Asgary S, Farzaei MH, Echeverría J. The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front Pharmacol. 2019;10:1207.

    Not in our library10.3389/fphar.2019.01207

28. 28.

    Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2018;15:93-114.

    Not in our library10.1080/17425247.2017.1360863

29. 29.

    Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017;4:105-131.

    Not in our library10.1177/2049936117713593

30. 30.

    Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the inhibition of viral infections. Molecules. 2015;20:14051-14081.

    Not in our library10.3390/molecules200814051

31. 31.
    Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics · 2017

    Corrected
32. 32.
    Nano based drug delivery systems: recent developments and future prospects · 2018

    No notice
33. 33.
    Nanomedicine: Principles, Properties, and Regulatory Issues · 2018

    No notice
34. 34.

    Fornaguera C, García-Celma MJ. Personalized nanomedicine: a revolution at the nanoscale. J Personal Med. 2017;7:12-20.

    Not in our library10.3390/jpm7040012

35. 35.

    Ben-Shabat S, Yarmolinsky L, Porat D, Dahan A. Antiviral effect of phytochemicals from medicinal plants: applications and drug delivery strategies. Drug Deliv Transl Res. 2020;10:354-367.

    Not in our library10.1007/s13346-019-00691-6

36. 36.
    Nanoformulations of curcumin: an emerging paradigm for improved remedial application · 2017

    No notice
37. 37.
    Anti-infective Properties of the Golden Spice Curcumin · 2019

    No notice
38. 38.

    Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product-based nanomedicine: recent advances and issues. Int J Nanomedicine. 2015;10:6055-6074.

    Not in our library10.2147/ijn.s92162

39. 39.

    Mokhtarzadeh A, Eivazzadeh-Keihan R, Pashazadeh P, Hejazi M, Gharaatifar N, Hasanzadeh M, et al. Nanomaterial-based biosensors for detection of pathogenic virus. Trends Anal Chem. 2017;97:445-457.

    Not in our library10.1016/j.trac.2017.10.005

40. 40.

    Kizek R, Krejcova L, Michalek P, Merlos Rodrigo M, Heger Z, Krizkova S, et al. Nanoscale virus biosensors: state of the art. NDD. 2015;4:47-66.

    Not in our library

Cited by papers we hold 4

• Nanoparticles: Taking a Unique Position in Medicine · 2023
  No notice
• Unique Properties of Surface-Functionalized Nanoparticles for Bio-Application: Functionalization Mechanisms and Importance in Application · 2022
  No notice
• Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review · 2022
  No notice
• Comprehensive and comparative studies on nanocytotoxicity of glyceryl monooleate- and phytantriol-based lipid liquid crystalline nanoparticles · 2021
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.